First-in-man randomized comparison of the Angiolite® durable fluoro-acrylate polymer-based sirolimus-eluting stent versus durable fluoropolymer-based everolimus eluting stent in patients with coronary artery disease: The ANGIOLITE trial.
The durable fluoro-acrylate polymer-based sirolimus-eluting stent (Angiolite®SES) has shown promising preclinical and clinical results regarding inflammatory vascular reaction and neointimal healing. We aimed to compare performance between SES and everolimus-eluting (EES) stents in patients with coronary artery disease. The ANGIOLITE trial, a prospective, randomized, multicenter trial, compared the restenosis parameters of both stents in de novo coronary lesions. Primary endpoint was late lumen loss at 6-month angiographic follow-up. In-stent healing was assessed by optical coherence tomography (OCT). Main clinical endpoint was target lesion failure (TLF) evaluated up to 24 months. A total of 223 patients were randomized 1:1 to EES or SES. At 6 months, in-stent late lumen loss was 0.08 mm (±0.38) for EES vs 0.04 mm (±0.39) for SES (Difference=-0.04 mm 95%CI [-0.15, 0.07], p for non-inferiority=0.002). By OCT, rate of uncovered to total number of struts score &gt;30% was comparable between groups whereas neointimal thickness was reduced in the SES arm (9.0% [7.6, 10.6] vs. 9.9% [8.5, 11.3], p=0.41; and 86.4 [81.6, 91.2] µm vs 72.1 [68.2, 76.0] µm; p&lt;0.01, respectively). At 24 months, TLF occurred in 8 patients (7.6% [3.3, 14.5]) in EES arm and in 7 patients (7.1% [2.9, 14.0]) in SES arm (p=0.88). Definite/probable stent thrombosis rate was comparable between groups (1.9% [0.2, 6.7] vs 1.0% [0.0, 5.5] EES vs. SES, respectively; p=0.59). This trial demonstrates similar anti-restenotic efficacy at mid-term follow-up of the Angiolite®SES vs. EES. Clinical endpoints were comparable between groups at 2-year follow-up.